AOD-9604Explore study findings
What the larger AOD-9604 obesity trial found
1 numbered sourceSource years 2024
Peptides are short chains of amino acids linked by peptide bonds. Some are modeled on parts of larger hormones so researchers can ask which effects belong to a particular sequence. AOD-9604 is a modified fragment of human growth hormone studied for weight management. The older clinical evidence summarized by the FDA includes the OPTIONS trial, which tested whether the peptide produced a measurable weight difference against placebo. [1]
The study enrolled adults with obesity and randomized 502 participants. Both the active groups and the placebo group also took part in a diet and exercise program supervised by a dietitian. That shared program made the comparison more informative. A change from the starting weight in an active group could reflect the program, other changes during the study, the investigational peptide, or some combination of those influences. The difference from the placebo group was the relevant measure of the peptide’s added effect under the conditions tested. [1]
The FDA’s briefing reported that the trial did not find a significant difference in weight loss at 12 weeks, the primary time point highlighted in the review. The sponsor stopped development for obesity after the failed study. The agency also discussed earlier studies, including an abstract that suggested a benefit but contained too little methodological detail for a confident interpretation. [1]
The larger randomized comparison is a direct human test of an oral formulation for obesity. The result limits what can be concluded from an encouraging early study or a proposed mechanism in fat cells. The FDA briefing is a regulatory account of the older clinical evidence, and the agency noted gaps in the public summaries and human evidence for other forms of administration. [1]
Sources
Original works cited in this article. Links open the external record in a new tab.
